Status:
TERMINATED
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
Lead Sponsor:
Carman Giacomantonio
Collaborating Sponsors:
Nova Scotia Health Authority
Conditions:
Melanoma (Skin)
Melanoma in Situ
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study is meant to assess the use of intralesional IL-2 to modulate the immunological response to suspected melanoma, or melanoma in situ, in an effort to increase lymphocyte infiltration and decr...
Detailed Description
This study is primarily designed to determine if tumor specific immunity can be generated in patients with highly suspicious pigmented lesions in response to intralesional IL-2, and whether that immun...
Eligibility Criteria
Inclusion
- The participant population will include patients characterized by: nodular/polypoid features, bleeding/ulcerated lesions, excluding face and vulvo-genital lesions.
Exclusion
- Participants who are not: currently immunocompromized, on immuno-therapy for other diagnosis, have known inflammatory or autoimmune diseases or are otherwise incapacitated.
Key Trial Info
Start Date :
October 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 27 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03233828
Start Date
October 30 2019
End Date
November 27 2019
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H3G1